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A B S T R A C T
The aim of this study was to assess the feasibility of rapid sodium MRI (23Na-MRI) for the imaging of peritoneal
cancer deposits in high grade serous ovarian cancer (HGSOC) and to evaluate the relationship of 23Na-MRI with
tumour cellularity. 23Na-MRI was performed at 3 T on twelve HGSOC patients using a 3D-cones acquisition
technique. Tumour biopsies specimens were collected after imaging and cellularity was measured from his-
tology. Total 23Na-MRI scan time for each patient was approximately 11min. At an isotropic resolution of
5.6mm, signal-to-noise ratios (SNRs) of 82.2± 15.3 and 15.1±7.1 (mean ± standard deviation) were
achieved for imaging of tumour tissue sodium concentration (TSC) and intracellular weighted sodium con-
centration (IWS) respectively. Tumour TSC and IWS concentrations were: 56.8 ± 19.1mM and 30.8 ± 9.2mM
respectively and skeletal muscle TSC and IWS concentrations were 33.2 ± 16.3mM and 20.5 ± 9.9mM re-
spectively. There were significant sodium concentration differences between cancer and skeletal muscle,
Wilcoxon signed-rank test, P < 0.001 for TSC and P= 0.01 for IWS imaging. Tumour cellularity displayed a
strong negative correlation with TSC, Spearman’s rho = -0.92, P < 0.001, but did not correlate with IWS. This
study demonstrates that 23Na-MRI using 3D-cones can rapidly assess sodium concentration in peritoneal deposits
of HGSOC and that TSC may serve as a biomarker of tumour cellularity.
1. Introduction
In the developed world, ovarian cancer is the fifth leading cause of
cancer-related mortality in women and high grade serous ovarian
cancer (HGSOC) is responsible for 70–80% of these deaths [1]. HGSOC
originates in the secretory cells of the fallopian tubes and metastasises
to the peritoneum and ovaries early on in the course of the disease [2].
The peritoneal deposits of HGSOC are typically superficially located
and easily accessible to percutaneous biopsy. For this reason, peritoneal
HGSOC tissue is often sampled for diagnostic purposes in preference to
the deeper and less accessible ovarian deposits.
HGSOC lesions demonstrate significant intra- and intertumoural
heterogeneity that can affect progression and survival [3]. Multi-re-
gional sampling of tissue and repeat sampling during therapy however
is often not practical due to the invasive nature of the biopsy procedure.
Imaging provides an alternative to biopsy for investigating entire het-
erogeneous tumour volumes and for non-invasively evaluating cancer
progress over time.
In human tissue the sodium ion concentration is approximately ten
times higher in the extracellular compartment compared to the in-
tracellular space. Intracellular sodium concentration [Na+IC] is usually
around 5–15mM and extracellular sodium concentration [Na+EC] ranges
from 135 to 155mM. Overall tissue sodium concentration (TSC) is a
weighted average of the intracellular sodium concentration and the
extracellular sodium concentration. The weighting in this average is
related to the cellularity of the tissue as higher cellularity corresponds
to a greater fraction of intracellular space and consequently a lower
TSC. Measurements of TSC could therefore potentially be used to probe
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cellularity and changes in cellularity such as with cell death in response
to chemotherapy.
The free movement of sodium between the intracellular and extra-
cellular compartments is normally restricted by the phospholipid bi-
layer of the cell membrane which is poorly permeable to sodium. The
majority of sodium ions that cross the cell membrane do so through
specialized ion transporters like the Na+/K+-ATPase pump, also known
as the sodium pump. Cell membrane porosity increases occurs early on
in the process of cell death, allowing greater sodium movement into the
cell down the electrical and concentration gradients that exist across
the membrane. This intracellular influx of sodium is associated with an
osmotic movement of water that contributes to cell swelling prior to
death [4]. An increase in TSC has previously been shown to be an early
marker of necrosis and part of the process of apoptosis [5,6]. Sodium
MRI (23Na-MRI) can measure TSC and the ability of 23Na-MRI to assess
tissue viability in the brain after acute stroke has already been de-
monstrated in several studies [7,8]. In murine models of glioma and
prostate cancer, 23Na-MRI has also successfully detected the response of
tumour to chemotherapy [9,10]. In HGSOC, the most effective ther-
apeutic strategies combine surgery and chemotherapy [11]. If TSC
measured using 23Na-MRI can detect cell viability and cellularity in
HGSOC, then 23Na-MRI may be of clinical value for monitoring both the
early and late tissue changes following successful chemotherapy treat-
ment, as responding cells first undergo an increase in sodium and
swelling before death, followed by a decrease in tumour cellularity and
intracellular volume fraction as the process of death completes.
In 23Na-MRI, the intracellular weighted sodium (IWS) signal can
also be separated from the overall tissue sodium signal using an in-
version recovery pulse sequence that exploits a difference in the T1
relaxation times of free and bound sodium. Increased TSC and IWS
concentrations compared to normal tissue have been found using 23Na-
MRI in several cancers including brain, breast and prostate [12–14]. In
the abdomen however, 23Na-MRI has proved technically challenging.
23Na-MRI generates a signal which is 22,000-fold smaller than con-
ventional proton MRI (1H-MRI) [15] and the sodium nucleus rapidly
loses signal after radiofrequency (RF) excitation because of a high
sensitivity to electrical fields.
Longer scan times that permit signal averaging can compensate for
the low 23Na-MRI signal. Previous studies of the abdomen have re-
ported scan times of 16–25min for the generation of quantitative so-
dium maps [16–18]. Such long scan times unfortunately may not al-
ways be feasible in clinical settings. A 3D-cones trajectory approach to
23Na-MRI in the brain however was recently shown to improve acqui-
sition times compared to the more widely used 3D-radial k-space
sampling methods, without any compromise in image quality [19].
Here we investigate the application of 23Na-MRI using 3D-cones to the
imaging of peritoneal cancer deposits in HGSOC and explore the re-
lationship of histologically measured tumour cellularity with the ima-
ging.
2. Materials and methods
2.1. Study conduct
This was a single centre prospective observational study
(ClinicalTrials.gov Identifier: NCT03526809) with institutional review
board (IBR) approval (South Cambridge Research Ethics Committee
reference number 15/EE/0378). All study related procedures were
performed with the written informed consent of participants and in
accordance with the ethical guidelines outlined in the Declaration of
Helsinki. Consecutive HGSOC patients presenting from August 2016 to
August 2017 with no contraindications to MRI and no previous treat-
ment for their cancer were invited to participate.
2.2. Image acquisition
23Na-MRI and 1H-MRI were carried out on all patients using a 3 T
MR system (MR750 GE Healthcare, Waukesha WI). The 23Na-MRI was
performed with a custom made single-channel transmit/receive surface
coil using a 3D-cones readout [20] and an adiabatic pulse for inversion
at a prescribed isotropic resolution of 5.6mm. T2-weighted 1H-MRI was
performed with a fast spin echo pulse sequence and a 32-channel car-
diac array. Patients were not moved or repositioned during the coil
change. The radiofrequency (RF) power used for the 23Na-MRI was
adjusted for each patient to achieve penetration up to a maximum
depth of 12 cm which was sufficient to image the peritoneal lesions in
all cases. Detailed scan parameters for sodium and proton imaging are
given in Table 1.
Sodium calibration phantoms were included in the field of view
(FoV) to enable calculation of sodium concentration maps. Phantoms
consisted of 50mL tubes of diameter 6 cm containing sodium chloride
(NaCl) with 4% agar at two sodium concentrations: 20mM and 80mM.
Image processing and noise correction
Sodium image reconstruction and post-processing were performed
with in-house software written in MATLAB v9.2 (The MathWorks Inc.,
Natick, MA). The method described by Miller et al. was applied for
noise correction [21]: this correction involved squaring the signal de-
rived from the image, measuring the squared mean pixel value from a
region of interest (ROI) in the background (outside the patient) for each
slice, subtracting this value from all pixels in the squared image and
calculating the square root. All signal-to-noise ratios (SNRs) reported in
the results section of this study were calculated prior to noise correction
as the mean signal divided by the standard deviation of background
signal [22].
Radiofrequency field inhomogeneity correction
To compensate for RF inhomogeneity in the FoV, a B1 correction
was applied to the sodium images. A dual flip angle gradient echo
method [23] with images collected at nominal flip angles ( nom) of 30°
and 60° was used for the B1 mapping to create an RF map (B1 map) of
Table 1
Imaging parameters for TSC (total sodium concentration), IWS (intracellular weighted sodium) and T2-weighted imaging. TR= repetition time, TE= echo time,
TI= inversion time, FoV=field of view, NEX=number of excitations, ETL= echo train length, GE= gradient echo.
Imaging parameter 23Na-MRI TSC and B1 mapping 23Na-MRI IWS 1H T2-weighted
TR 100 ms 250 ms 4000 ms
TE 0.5 ms 0.5 ms 91.1 ms
TI n/a 30 ms n/a
Flip angle 90° for TSC, 30° and 60° for B1 mapping 90° 90°
Slice thickness 5.6mm 5.6mm 6mm
In plane resolution 5.6mmx5.6mm 5.6mm x 5.6mm 1.33mm x 1.33mm
FoV 30 cm 30cm 34.0 cm x 29.9 cm
Matrix 50×50 (reconstructed to 120×120) 50× 50 (reconstructed to 120×120) 256×256
NEX 6 6 8
ETL n/a n/a 16
Total scan time 1min 58 sec 4min 56 sec 1min 54 sec
Pulse sequence GE with 3D-Cones readout IR- GE with 3D-Cones readout Single shot fast spin echo (SSFSE)
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the true flip angle true. Regions on the B1 maps which had very low
effective flip angles (< 10°) or high flip angles (> 140°) where dual
angle mapping is inaccurate [24] were excluded from subsequent
analysis.
A correction formula was derived to use true to compensate for the
non-uniformities in both the transmit and the receive fields. To do this,
the expression for the spoiled gradient echo (GE) steady state signal was
combined with the relationship of signal to the receive-only B1 of a
surface coil [25]. For the sodium pulse sequence used here TR> >T1,
causing the overall relationship of the combined receive and transmit




. ( )true true
+
(1)
Where S is the sodium image signal. Eq. (1) was applied to correct the
sodium signal images before conversion into sodium concentration
maps.
2.3. Region-of-interest analysis
Sodium maps (TSC and IWS) were calculated from a linear cali-
bration curve created with the sodium in agar phantoms based on the
method described by Christensen JD et al. [26]. ROIs were drawn on
the T2-weighted images by a single observer using OsiriX (version 3.8.1,
Pixmeo, Geneva, Switzerland) around the complete peritoneal deposits
and around the adjacent areas of right gluteal muscle as a normal re-
ference tissue for comparison with the tumour. ROIs were reviewed by
a radiologist with eight years of experience as an attending physician
and co-registered with the sodium maps to which the ROIs were im-
ported for analysis. For patients with multiple peritoneal deposits, ROIs
were combined into a single tumour volume.
2.4. Tissue handling
Tissue samples were collected from the peritoneal deposits of pa-
tients 1–14 days (median 7 days) after imaging either by ultrasound
guided biopsy or at surgery. Samples were fixed in paraffin blocks for
storage and cut into 3 μm sections that were retrieved with sodium
citrate. Sections were stained with haematoxylin and a cell count and
tissue area quantification were performed on the sections using auto-
mated histology image analysis software (Halo, v2.1.1637.11, Indica
labs). Cellularity (cell density), c was estimated from the cell count (N)
and tissue area (A) in μm2 as follows:
N A x/ 1000c = (2)
2.5. Statistics
All statistical analysis was performed in R (v2.15.3, R Foundation
for Statistical Computing, Vienna, Austria). For comparison of means,
the Shapiro-Wilk test was used to assess data for normality and the
Student’s t-test or Wilcoxon test was then applied to evaluate sig-
nificance. Cellularity was compared to sodium concentrations from
23Na-MRI (TSC and IWS) using Spearman’s correlation.
3. Results
3.1. Patients
Twelve high grade serous ovarian cancer patients were recruited:
median age 69 (range 52–81) years. Table 2 gives detailed sample
population characteristics.
3.2. Imaging
The total 23Na-MRI imaging time for each patient was under 11min
(TSC imaging time=1min 58 s, IWS imaging time=4min. 56 s, time
for images for dual flip angle mapping= 3min 56 s). Signal-to-noise
ratios of 82.2 ± 15.3 and 15.1 ± 7.1 were achieved for tumour TSC
and IWS imaging respectively. High signal intensity artefacts appeared
at the edges of images after RF field inhomogeneity corrections because
of small mismatches in alignment between B1 maps and sodium signal
images at the interfaces of high sodium signal changes such as between
air and tissue. These mismatches were due to patient movement and
were found exclusively at imaging borders and therefore were not
present in ROIs derived from peritoneal deposits or muscle. Examples of
the 23Na-MRI images and changes with post-processing are shown in
Fig. 1.
3.3. Sodium quantification and tumour cellularity
The TSC for peritoneal cancer deposits and gluteal skeletal muscle
were 56.8 ± 19.1mM and 33.2 ± 16.3mM respectively (mean ±
standard deviation); Wilcoxon signed-rank test, P < 0.001. IWS values
for peritoneal cancer and muscle were 30.8±9.2 mM and 20.5± 9.9
mM respectively; Wilcoxon signed-rank test, P= 0.01. These results
are summarised in the boxplots of medians and interquartile ranges
shown in Fig. 2.
An example of the typical histological appearances for a 73-year old
HGSOC patient are shown in Fig. 3 together with the automated cell
counting segmentation, demonstrating the accuracy of the software at
detecting cells. Scatterplots of tumour cellularity ( c) compared with
sodium concentrations as measured on imaging are shown in Fig. 3(C)
and 3(D). TSC displayed a strong negative correlation with cellularity,
Spearman’s rho = -0.92 and P < 0.001. There was no significant
correlation found between IWS concentration and cellularity, P= 0.44.
4. Discussion
This study demonstrated the feasibility of using 23Na-MRI to image
peritoneal lesions in high grade serous ovarian cancer patients for the
first time. The completion of sodium imaging in approximately eleven
minutes was achieved with a combination of a 3D-cones readout, a
surface transmit/receive coil and a post-processing analysis method to
correct for RF field non-uniformity. Short acquisition times are im-
portant for the clinical translation of 23Na-MRI and these results re-
present a moderate improvement to previously reported scan times in
the abdomen [16–18]. The comparison of tumour sodium quantifica-
tion to histology that was performed here, also provided validation that
TSC measured by 23Na-MRI is an effective biomarker for tumour cel-
lularity.
Cellularity has already been shown to relate to the outcome of
Table 2
Population demographics of patients recruited. ECOG=Eastern Cooperative
Oncology Group, FIGO=Fédération Internationale de Gynécologie et
d'Obstétrique, CA 125 = cancer antigen 125.
Feature Value
Number of patients 12
Age, median (range, years) 69 (52-81)
ECOG performance status (number of patients)
0–2 9
3–4 3
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Fig. 1. 73-year old high grade serous ovarian cancer patient. P1 and P2 represent slices through the two sodium phantoms. The green outline shows a peritoneal
cancer deposit. (A) T2-weighted image. (B) Sodium B1 map, scale bar represents arbitrary units. (C) Total sodium image; scale bar represents image intensity. (D)
Intracellular weighted sodium image; scale bar represents image intensity. (E) Masked total sodium concentration map; scale bar represents sodium concentration in
mM. (F) Masked intracellular weighted sodium concentration map, scale bar represents sodium concentration in mM. (G) Fused T2W image and total sodium
concentration map. (H) Fused T2W image and intracellular weighted sodium concentration map. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article).
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cytoreduction in HGSOC [27] and to be predictive of the response of
breast cancer to neoadjuvant chemotherapy [28]. In breast cancer,
cellularity is also used more directly in the Miller-Payne method for the
histological assessment of treatment response [29]. For HGSOC treat-
ment, the first line chemotherapy regimen of a combination of a pla-
tinum-based drug and a taxane has not changed for the past 30 years
despite poor patient outcomes [30]. There is now ongoing research to
develop more targeted HGSOC therapies such as PARP (poly ADP-ri-
bose polymerase) inhibitors [31], VEGF (vascular endothelial growth
factor) inhibitors [32] and immune checkpoint inhibitors [33], to im-
prove the outlook for this disease.
With the emergence of new therapies in heterogeneous cancers like
HGSOC, there is an associated need for imaging to provide greater
detail on tumour structure and function so that patients can be better
stratified to the optimal treatment for their particular subtype of dis-
ease. The availability of alternative therapies also provides the oppor-
tunity for non-responsive patients to switch to more effective drugs and
imaging tests that can assess response are therefore similarly required.
The measurement of cellularity with 23Na-MRI demonstrated here
provides information on tumour composition and can be employed to
monitor the evolution of tumour cellularity over time and following
treatment. This could additionally have implications for patient man-
agement in other malignancies where the detection of cell death and
the monitoring of cellularity changes are of clinical relevance like in
breast cancer.
Apart from cellularity, 23Na-MRI also reflects the activity of trans-
porters such as the Na+/K+-ATPase pump, and possibly by extension
ATP levels, which may be altered earlier than cellularity in some phy-
siological processes like cell death. 23Na-MRI could therefore poten-
tially report on response to treatment earlier than other imaging
methods like diffusion weighted MRI, which primarily also detects
cellularity and probe processes like metabolism and transporter activity
which diffusion cannot.
Despite the strong significance of the relationship between TSC and
cellularity found here, no correlation between cellularity and IWS could
be detected. IWS concentration in cancer is influenced by a large
number of biological processes that may have a greater relative effect
on the small IWS concentration and imaging signal than cellularity. For
example, the IWS signal may be affected by the energy status of tu-
mours due to the ATP and oxygen requirements of the sodium pump
[34]. In cancer, there may be mitochondrial dysfunction [35] as well as
metabolic reprogramming that shifts glucose away from the production
of ATP by oxidative phosphorylation and towards the manufacture of
new nucleotides, lipids and amino acids needed for cell replication and
unregulated tumour growth [36,37]. Voltage gated sodium channel
expression is also upregulated in many cancers [38,39] and although
the purpose of these channels in cancer is not yet clear, they may re-
present another mechanism by which the intracellular sodium con-
centration is altered in malignancy. Furthermore, aggressive tumours
such as HGSOC have higher Na+/H+ antiporter activity which allows
sodium to enter the cell in exchange for H+ efflux, and creates an acidic
extracellular environment that facilitates tumour invasion [40].
TSC signal is dominated by the high concentration of sodium in the
extracellular space and is less susceptible to the transmembrane
movement of sodium as it is a measure of the total tissue sodium in each
voxel, including signal from sodium in both the intracellular and ex-
tracellular environments. By comparison, the IWS pulse sequence nulls
the large extracellular sodium pool with its inversion recovery, re-
sulting in a much lower SNR and greater susceptibility of IWS mea-
surements to noise.
The conclusions that can be drawn from the findings in this study
are limited by the possibility of errors introduced through patient
movement during the sodium/proton coil change and the creation of
edge artefacts in post-processing. The optimisation of RF power to
image superficial peritoneal lesions also meant that muscle sodium
measurements could not include deeper muscle regions. Reasonable
measures were taken to minimise the effects of these limitations by
masking possible inaccurate sodium map areas and the application of
an RF inhomogeneity correction.
5. Conclusion
In conclusion, rapid 23Na-MRI using 3D-cones was successfully
performed in a technically challenging area of the body. This study
shows for the first time that 23Na-MRI can assess peritoneal deposits of
HGSOC patients and that the TSC measured by 23Na-MRI correlates
strongly with tumour cellularity. The non-invasive quantification of
sodium using MRI has the potential to provide information on cell
viability, sodium transporters, metabolic activity, cell membrane in-
tegrity and tumour response to therapy. The rapid scanning method
shown here demonstrates that larger human studies to evaluate 23Na-
MRI in the abdomen are feasible and should be supported. Further work
is needed to investigate other clinical applications of sodium MRI, to
explore the utility of TSC in monitoring cellularity changes in response
to specific cancer treatments and to validate the cellular changes that
can be measured with 23Na-MRI.
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